Download Funding News NEWS & NOTICES FROM WEEK ENDING February 16 2007

Funding News
February 21, 2007
NEWS & NOTICES FROM WEEK ENDING February 16 2007
NIH NCI Will Replace the NCI Howard Temin (K01) Award with the NIH Pathway to Independence
K99/R00 Award (2/12) Because there are NCI-specific submission requirements for K99/R00 applications,
applicants should refer to PA-07-297, as well as to the NCI portion of the contacts information for that PA
(http://grants.nih.gov/grants/guide/contacts/pa-07-297_contacts.htm). The next receipt date is March 12.
The NCI continues to accept K01 applications, but only in response to PAR-06-220, which is entitled “NCI
Mentored Career Development Award to Promote Diversity (K01).” Details in NOT-CA-07-010 .
NIH Publishes Observations from Targeted Site Reviews on Financial Conflict of Interest
[NOT-OD-07-048] (2/16) The site reviews focused specifically on compliance with the Financial Conflict of
Interest regulation (42 CFR Part 50 Subpart F, Responsibility of Applicants for Promoting Objectivity in
Research for which PHS Funding is Sought). Information published at
http://grants.nih.gov/grants/policy/coi/index.htm.
NIH Will Publish RFA for NIH Director’s New Innovator Awards this Spring [NOT-OD-07-047] (2/16)
This new program extends the concept of the NIH Director’s Pioneer Awards to support new investigators
who propose innovative approaches that have the potential to produce an unusually high impact on
significant problems in biomedical and behavioral research—and who have not yet obtained a traditional
R01 grant. Applicants must hold an independent research position at a domestic institution, and be within
10 years of their terminal degree (l997 or later). Awards will be up to $300K a year for 5 years. Review and
funding expected by September 2007.
NIH NIEHS RFI: Functional Validation of Environmentally-Responsive Genetic Variants (2/12)Through
April 20, NIEHS is soliciting information regarding how polymorphisms or genetic variants identified through
genetic association studies, candidate gene studies, or epidemiological studies for environmentallyrelevant diseases can best be validated in functional prescreens and studies. More information in NOT-ES07-006.
NIH NIAID New RFA: Exploratory Investigations in Food Allergy [NOT-AI-07-023] (2/12)
This R21-based program supports exploratory and developmental investigations to determine the
mechanisms underlying food allergy, focusing on ex vivo studies with human specimens and on studies
with current or new animal models of human food allergy
NIH NIAID RFP: Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases (2/13)
The NIAID Division of Microbiology and Infectious Diseases (DMID) supports extramural research to control
and prevent diseases caused by virtually all infectious agents other than HIV. The scope includes basic and
applied research to develop and evaluate therapeutics, vaccines, and diagnostics. NIH will provide and
manage a Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases. This phase I unit will
operate under Good Clinical Practices (GCP) and will provide and support electronic data capture system.
More information in NOT-AI-07-024.
RECENT SOLICITATIONS
NIH NCI Lung and Cancer Inflammation – R01 [PAR-07-214] (2/13)
LOI Date
Receipt Date
Earliest Start Date
Closing Date
March 23, 2007
April 23, 2007
December 1, 2007
April 24, 2007
Established by the newly-formed NCI Lung Cancer Program at the National Cancer Institute (NCI), this FOA
is designed to increase our understanding of the basic processes in the pathogenesis of lung cancer,
especially the early events. New insights are needed into the early cell biological and molecular changes
that may occur in lung cells (including putative lung stem cells), as they progress from a normal phenotype
to a malignant one under the inflammatory influence. The NCI has identified this area as being critical for
further advances in the early diagnosis, prevention, and treatment of lung cancer.
Examples of Appropriate Investigative Themes
• What are the cytokines and small molecules present in the lung tissue microenvironment during
chronic inflammation that directly contribute to lung carcinogenesis?
• What intracellular mechanisms may be triggered by inflammatory cytokines, small molecules, or
oxidative stress, which contribute to cell transformation in the lung epithelium?
• What is (are) the critical inflammatory step(s) required to produce an irreversible cellular
commitment to lung tumor formation?
• How does inflammation alter the lung stem cell niche to foster the expansion (or alter the
differentiation) of transformed lung stem cells?
• Can more differentiated cells in the lung become lung tumor stem cells, and how does an
inflammatory microenvironment facilitate this transition?
Commitment
$10M to fund 3-5 grants
NIH NIDDK, NCI, NCCAM, NHLBI, NIA, NIAAA, NICHD, NINDS, ODS Diet Composition and Energy
Balance – R01 [PA-07-218] (2/14)
Opening Date
Receipt Date
Closing Date
May 5, 2007
June 5, October 5, February 5
March 6, 2010
Invites applications investigating the role of diet composition in energy balance, including studies in both
animals and humans. Both short and longer-term studies are encouraged, ranging from basic studies
investigating the impact of micro-or macronutrient composition on appetite, metabolism, and energy
expenditure through clinical studies evaluating the efficacy of diets differing in micro- or macronutrient
composition, absorption, dietary variety, or energy density for weight loss or weight maintenance.
Some of the Types of Projects to be Funded
•
•
•
•
•
•
•
•
•
•
•
•
Studies addressing the impact of diets varying in levels of protein, carbohydrate, fat, phytochemicals, or
ethanol on appetite, food selection and intake, and energy expenditure.
Studies examining the role of diets differing in glycemic index, dietary variety, food volume, or nutrient
density on appetite, caloric intake, nutrient absorption, weight, metabolomic profiles, and body
composition both short- and long-term.
Investigation of the impact of diet composition on neuroendocrine, gastrointestinal, and other factors
that may impact energy balance.
The impact of food components such as conjugated linoleic acid (either from food or supplement
sources) or calcium (either from dairy or non-dairy sources, including dietary supplements) on energy
balance, body composition, and disease risk.
Studies assessing genomic and epigenomic factors underlying individual or population differences in
response to diet composition that relate to chronic disease prevention.
Studies using animal models of obesity to examine the relationship between diet, energy balance, and
cancer prevention
Brain imaging studies in humans and non-human primates to assess positron emission tomography,
functional magnetic resonance, or cerebral blood flow imaging responses to specific dietary
constituents.
Studies to develop methods to assess dietary composition.
Studies measuring the effects of sleep deprivation, either by experimental manipulation or due to a
disease process on macronutrient consumption (e.g., does sleep deprivation lead to changes in
cravings for carbohydrate and fat? Does sleep deprivation lead to change in body weight?).
Studies assessing dietary composition effects on the magnitude and time course of neurobehavioral
and physiological responses to sleep loss, and the interaction of these effects with BMI, gender, age,
and ethnicity.
Studies assessing life-stage, racial/ethnic, and gender-related factors underlying response to diet
composition, including studies in children, adolescents, and adults of various ages.
Validation of medium or long-term effects of different dietary macronutrient composition on energy
2
intake in community-dwelling individuals using doubly labeled water.
CDC ATSDR Improving Public Health Practice through Translation Research – R18
[RFA-CD-07-005] (2/16)
Opening Date
LOI Date
Receipt Date
Earliest Start Date
Closing Date
February 16, 2007
March 12, 2007
April 10, 2007
September, 2007
April 11, 2007
Promotes translation research that uses an evidence-based intervention or policy. Proposed research
should identify: 1) impediments and/or facilitators to the successful translation of evidence-based public
health intervention(s); 2) methodological tools for the successful translation of evidence-based programs,
practices, or policies; that retain fidelity, and achieve positive outcomes for target populations; or 3) optimal
strategies to enhance the widespread adoption and institutionalization of effective public health intervention
programs.
Commitment
Award
Total of $10M
Three (3) years of up to $450K a year in total costs
NIH NICHD Fragile X Pre-mutation and Ovarian Function – R01, R03 [PA-07-219], [PA -07-220]
(2/16)
Opening Date
Receipt Date
Closing Date
February 15, 2007
June 5, October 5, February 5
June 16, October 16, February 16
March 6, 2010; March 17, 2010
Designed to stimulate research regarding the molecular mechanisms by which the Fragile X pre-mutation
impairs normal ovarian function.
Potential Topics of Interest
•
•
•
•
•
•
Epidemiological or familial studies of penetrance—why some carriers of the Fragile X pre-mutation
experience premature ovarian failure or early menopause while others do not.
Studies of factors (genetic or environmental) that alter the expression or function of the FMR1 gene
product to affect ovarian physiology.
Longitudinal studies of pre-mutation carriers or case control studies of the kinetics of ovarian follicle
loss and the precursors to frank ovarian failure, particularly those that could lead to the development of
mathematical, predictive models for future ovarian function in carriers to provide a basis for genetic
counseling on reproductive potential.
The development of animal models with the Fragile X pre-mutation, and their phenotypic and molecular
characterization.
Studies of ovarian function and histology, reproductive function and reproductive aging, and oocyte
quality in animal models with the Fragile X pre-mutation or in affected women.
Basic studies of the mechanisms through which the expansion of the Fragile X triplet repeat affects
gene expression and thereby ovarian function—such as the possibility of nuclear aggregates,
cytotoxicity, effects on the expression of other X chromosome genes, or effects on chromosomal
recombination.
3
GENERAL INFORMATION○
Unless otherwise specified, for each program description summarized in Funding
News, the following guidelines apply:
•
•
•
•
•
•
•
•
•
Dollar amounts represent direct costs.
NIH R01 awards are for unspecified amounts that are dependant on
available funding and the nature of applications received; they are
renewable.
NIH R03 awards are up to of $100K over two years and are nonrenewable.
NIH R21 awards are up to $275K over two years and are nonrenewable.
NIH AIDS-related proposals are associated with the standard receipt dates
May 1, September 1 and January 2 (extended to January 3 for 2006 only).
Applicants/Institutions can submit more than one application.
All applicants with the skills, knowledge and resources necessary to
perform proposed research are eligible.
No institutional restrictions other than the general NIH standards apply.
Not every NIH Institute and Centers supports all types of funding
mechanisms. For example, when co-sponsoring an initiative, NEIHS may
offer both R01 and R03 award mechanisms, whereas NIE will offer only the
former.
○
2
Applicable unless otherwise specified
No. 8, February 21, 2007
Heidi Davis, Editor
Office of Grants and Development
[email protected]
4